SIGNIFICANCE OF RELAPSE FOLLOWING ADJUVANT THERAPY WITH CMF OR 5-FU IN HIGH-RISK BREAST-CANCER

被引：0
|
作者：
CHLEBOWSKI, RT [1 ]
WEINER, JM [1 ]
LUCE, J [1 ]
HESTORFF, R [1 ]
LANG, JE [1 ]
REYNOLDS, R [1 ]
GODFREY, T [1 ]
RYDEN, VMJ [1 ]
BATEMAN, JR [1 ]
机构：
[1] WESTERN CANC STUDY GRP,LOS ANGELES,CA 90509
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1981年 / 22卷 / MAR期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：146 / 146
页数：1
相关论文
共 50 条
  • [31] SODIUM DITIOCARB AS ADJUVANT IMMUNOTHERAPY FOR HIGH-RISK BREAST-CANCER - A RANDOMIZED STUDY
    DUFOUR, P
    LANG, JM
    GIRON, C
    DUCLOS, B
    HAEHNEL, P
    JAECK, D
    JUNG, JM
    OBERLING, F
    BIOTHERAPY, 1993, 6 (01) : 9 - 12
  • [32] Importance of 5-FU (5-fluorouracil) infusion duration and toxicity during cmf (cyclofosfamide, methotrexate, 5 fluorouracil) administration in adjuvant setting of breast cancer
    Capobianco, A.
    Bochicchio, A. M.
    Coccaro, M.
    Di Leo, P.
    Ardito, R.
    Romano, G.
    Tartarone, A.
    Musto, C.
    Barone, M.
    Guariglia, R.
    Di Renzo, N.
    ANNALS OF ONCOLOGY, 2005, 16 : 8 - 8
  • [33] Doxorubicin vs CMF in the adjuvant treatment of high risk breast cancer
    Semiglazov, VF
    Bozhok, AA
    Ivanova, OA
    Iranov, VG
    Golubeva, OM
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S41 - S41
  • [34] THE BENEFIT OF L-PAM PLUS 5-FU PLUS TAMOXIFEN (PFT) ADJUVANT THERAPY IN STAGE-II BREAST-CANCER PATIENTS
    FISHER, B
    PLOTKIN, D
    BOWMAN, D
    SACHS, S
    WOLTER, J
    FRELICK, R
    DESSER, R
    CAMPBELL, T
    PRAGER, D
    DIMITROV, N
    LERNER, H
    GEGGIE, P
    ELIAS, EG
    GLASS, A
    POISSON, R
    REDMOND, C
    WOLMARK, N
    BROWN, A
    WITTLIFF, J
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 438 - 438
  • [35] Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer
    Fountzilas, G
    Papadimitriou, C
    Aravantinos, G
    Nicolaides, C
    Stathopoulos, G
    Bafaloukos, D
    Kalofonos, H
    Ekonomopoulos, T
    Skarlos, D
    Pavlidis, N
    Dimopoulos, AM
    ONCOLOGY, 2001, 60 (03) : 214 - 220
  • [36] Doxorubicin vs CMF in the adjuvant treatment of high risk breast cancer
    Semiglazov, VF
    Bozhok, AA
    Moiseyenko, VM
    Ivanova, OA
    Ivanov, VG
    Golubeva, OM
    ANNALS OF ONCOLOGY, 1998, 9 : 5 - 5
  • [37] SEQUENTIAL METHOTREXATE AND 5-FU IN BREAST-CANCER RESISTANT TO THE CONVENTIONAL APPLICATION OF THESE DRUGS
    HERRMANN, R
    MANEGOLD, C
    SCHROEDER, M
    TIGGES, FJ
    BARTSCH, H
    JUNGI, F
    FRITZE, D
    CANCER TREATMENT REPORTS, 1984, 68 (10): : 1279 - 1281
  • [38] PROSPECTIVE TRIAL OF STANDARD VS LOW-DOSE CYTOXAN, METHOTREXATE, 5-FU (CMF) IN ADJUVANT THERAPY OF BREAST CANCER-ASSESSMENT OF THERAPEUTIC EFFICACY AND TOXICITY
    ABELOFF, MD
    MELLITS, ED
    BAUMGARDNER, R
    WILCOX, P
    WATKINS, S
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 440 - 440
  • [39] PHASE-2 STUDY OF MELPHALAN, METHOTREXATE AND 5-FU IN BREAST-CANCER
    DESAI, S
    TAYLOR, S
    GOLDSWEIG, H
    DEWYS, W
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1976, 17 (MAR): : 303 - 303
  • [40] An isolation strategy for biomarkers that predict cancer relapse after 5-FU based adjuvant chemotherapy
    Nishizuka, Satoshi Stephen
    Ishida, Kazushige
    Uesugi, Noriyuki
    Chiba, Takehiro
    Matsuo, Teppei
    Yamada, Noriyuki
    Otsuka, Koki
    Koeda, Keisuke
    Sugai, Tamotsu
    Wakabayashi, Go
    CANCER RESEARCH, 2011, 71
12345